- According to the National Cancer Institute, an estimated 1. 8 million people in the U.S. will be diagnosed with cancer in 2022. It’s a startling statistic. As a result, the market for new cancer treatments is expected to reach $194 billion by 2028, growing at a rate of 15% per year.
- Investors need to get up to speed in a hurry because pandemic and political headlines have buried stunning news… new advancements in cancer therapies have driven small-cap cancer treatment companies to gains of 453%, 505%, and 720% in the past 24 months.
- Now, Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC) could be next to soar, with the launch of a proprietary molecular technology that’s capable of evading cancer’s defenses, allowing cancer-fighting agents to release directly into the cell’s nucleus.
- The company just announced a massive breakthrough, with a first-of-its-kind vaccine that not only provides 100% protection from developing cervical cancer, but also shows positive effects in the treatment of individuals with already established tumors.
The biotech industry has been in a slump in recent months. The Nasdaq Biotechnology Index declined about 14 percent in the past year as investors’ attention and resources were redirected during towards clean energy and fintech.1
Yet all that may be about to change. A handful of smaller companies developing new vaccines and vaccine-related technologies for treating cancer, such as Defence Therapeutics, have been seeing renewed attention.
Investors like these stocks because of their low share costs and potential for sudden, explosive profits. It’s not uncommon for a cancer stock to have a single breakthrough that drives the price of its stock from a few dollars to $10 to $20 per share.
That’s why some investors are taking a close look at Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC). It’s been developing a new cellular delivery “platform” that could lead to breakthrough cancer treatments.
Founded in 2017 by a team of immune-oncologists, biochemists, pharmacists and surgeons, 2 the Vancouver-based company aims to be a key player in the development of next-generation cancer and infectious disease treatments.
The potential is enormous. At the moment, there are only a handful of anti-cancer vaccines on the market.
One is produced by a privately held company called Dendreon. The other is Gardasil-9 produced by Merck or Cervarix by GSK, which is an anti-viral vaccine that protects from cervical cancer.
The reason why there are so few cancer vaccines is not because effective treatment agents aren’t available. The problem is getting the biopharmaceuticals where they can do the most good, inside the right immune cells themselves.
It turns out cancer cells are very good at defending themselves against immune attacks. They can detect approaching drug molecules and neutralize them in a kind of protective sac, rendering them useless.
That’s why Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC)’s new AccumTM platform could be a game-changing technology with applicability to dozens of life-threatening ailments.
In essence, AccumTM is a tiny molecule that functions like a kind of microscopic sponge. It can “soak up” any number of potent anti-cancer and anti-viral agents.
Plus, AccumTM does much more than that. It has the ability to evade a cancer cell’s defenses by escaping the membrane “sac,” known as an endosome, that a cancerous cell uses to envelope and isolate drug compounds attacking it.
Then AccumTM (along with the treatment it is “carrying”) penetrates directly into the cell’s nucleus, releasing the cancer-dissolving agents inside the nucleus itself.
Delivering Breakthrough Treatments Where They Can Be The Most Effective
An example of just how revolutionary Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC)’s new AccumTM platform could be, can be seen with a new class of biopharmaceuticals known as ADCs – or Antibody Drug Conjugates.
These hybrid treatments are just what they sound like: they combine a natural antibody that targets a specific type of cancer with a cytotoxic drug that destroys the cancer cells. The problem is getting the ADC inside the cancer cells where they can be most effective.
In early laboratory tests, by combining an ADC with the AccumTM platform molecule, researchers have seen a dramatic increase in the effectiveness of some ADCs – by as much as 10 to 100 times!
At the moment, Defence Therapeutics is collaborating with the HUS Comprehensive Cancer Center in Helsinki, Finland, to test and optimize an AccumTM-enhanced version of an ADC treatment for breast and gastric cancer.
This is a potentially huge breakthrough.
The AccumTM platform could boost the effectiveness of other new cancer treatments and technologies by up to 10 to 200 times, including super-advanced gene therapies.
In other words: Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC) could become a key player in the delivery of cancer-fighting technologies developed by other companies.
In effect, it would be the “FedEx” of the pharmaceutical industry, providing fast and reliable delivery of products that fight cancer and other deadly diseases.
And for investors, this is an exciting development for obvious reasons.
The Cancer Treatment Market is Expected to Triple in the Next Six Years to $195 Billion
According to the National Cancer Institute, a staggering 1.8 million people in the U.S. will be diagnosed with cancer in 2022.3 As a result, the market for new cancer vaccines and treatments is expected to grow to $163.1 billion by 2027, growing at a rate of 15% per year.4
And due to the recent pandemic, investors are now aware of just how important drug delivery “platforms” can be — such as the mRNA platform used for the Covid vaccine.
Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC) could potentially collaborate with many of the world’s largest pharmaceutical companies by helping them to enhance delivery of their vaccines by means of the AccumTM platform.
Developing state-of-the-art treatments for cancer and infectious diseases
In addition to the AccumTM platform itself, Defence Therapeutics also has half a dozen products of its own in development based on the AccumTM platform, including two in Phase I trials later in 2022 that focus on treatments for breast and skin cancer.
- First, the company has developed a series of four vaccines, dubbed AccuVACs, designed around the action of dendritic cells (DCs). These four vaccines are being developed for such deadly cancers as lymphoma, melanoma, breast, and colon cancer.
- The company also has two treatments in development based on antibody-drug conjugates (ADCs). These cutting-edge hybrid treatments will be for different breast and gastric cancers.
- The third group of treatments Defence Therapeutics is developing center around its AccuTOX agents. As its name implies, the AccuTOX agents are variants of the AccumTM molecule designed to trigger cell death directly in cancer cells, specifically targeting lymphoma and breast cancer cells.
- The fourth group of products the company is developing two new Covid-19 vaccines.
- And the fifth group is a breakthrough treatment for Human Papillomavirus (HPV). Preclinical studies on this new vaccine, not only provide a 100% protection from cervical cancer if delivered prophylactically, but also show potent effects against established tumors.
“The idea of having a dual-acting vaccine targeting cervical cancer capable of both protecting and treating patients from cervical cancer is a giant step in the field of cancer vaccines. In addition, this vaccine contains a single protein, the E7, which makes it easier to manufacture and use compared to a mix of 9 proteins as provided by the Gardasil-9 product,”
Each of these groups of treatments represent a huge market by itself. The market for breast cancer treatments alone is estimated to be $55.3 billion by 207, and the market for HPV vaccines projected to be $12.7 billion the same year.
For a small company such as Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC), developing a treatment in any one of these markets could be a breakthrough that drives its share price higher.
453%, 505%, and 720% gains in two years
A recent example of the potential of small cancer biotech stocks is Sierra Oncology, Inc. (OTC: SRRA), a late-stage biopharmaceutical company developing targeted therapies that treat rare forms of cancer.
It started out in early 2020 selling for only $9.035 per share. Yet by mid-April 2022, Sierra Oncology’s shares had skyrocketed to $54.706 per share – a 505%7 gain. Every $5,000 invested could have grown into as much $30,250 in just two years.
Nor was Sierra Oncology the only cancer stock to see huge gains even as the biotech industry pulled back over the last year.
CTI Biopharm Corp (CTIC), which focuses on the development and commercialization of therapies covering a spectrum of blood-related cancers, also handed investors sizable gains.
It was a penny biotech stock selling for only $0.888 a share back in early 2020.
But two years later, even as biotech stocks in general were struggling, CTI Biopharm Corp’s shares had jumped to $4.879 a share, a gain of 453%.10
The same thing happened with Sunshine Biopharma (SBFM), a Montreal-based company developing anti-cancer drugs based on the mRNA technology used to develop a Covid vaccine.
Its shares skyrocketed from only 50 cents11 per share at the end of April 2020 to $4.1012 per share less than two years later – a gain of 720%.
Of course, past performance is no guarantee of future results, and investing in small-cap companies in any industry should be considered risky. Despite the great promise, Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC) should still be considered a speculative investment.
Nevertheless, it’s not uncommon for small-cap biotech companies to see rapid growth in share value.
And with the price of many established Big Pharma stocks now reaching $50 to $300 per share, smaller early-stage biotech companies often offer attractive risk-to-reward ratios.
Do your due diligence, for more information about Defence Therapeutics (OTC:DTCFF, CSE:DTC, FSE:DTCOTC:DTCFF, CSE:DTC, FSE:DTC), check out the company’s website.
1 https://www.marketwatch.com/investing/index/nbi
2 https://defencetherapeutics.com/leaders-partnerships/
3 https://www.cancer.gov/about-cancer/understanding/statistics
4 https://www.zionmarketresearch.com/report/immuno-oncology-therapy-market
5 Price closed at $9.03 per share on April 1, 2020. Cf. https://www.barchart.com/stocks/quotes/SRRA/price-history/historical
6 Closed on April 19, 2022. https://www.barchart.com/stocks/quotes/SRRA/price-history/historicalv
7 https://www.calculator.net/percent-calculator.html?c3par1=9.03&c3par2=54.7&ctype=3&x=34&y=28#pctdifference
8 CTIC closed at $0.88 per share on April 16, 2020, per https://www.barchart.com/stocks/quotes/CTIC/price-history/historical
9 Close price on April 7, 2022, per https://www.barchart.com/stocks/quotes/CTIC/price-history/historical
10 https://www.calculator.net/percent-calculator.html
11 Close price on April 15, 2020, per https://www.barchart.com/stocks/quotes/SBFM/price-history/historical
12 Close price on April 19, 2022, per https://www.barchart.com/stocks/quotes/SBFM/price-history/historical
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Defence Therapeutics (“DEFT”) and its securities, DEFT has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by DEFT ) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of any profiled company DEFT and has no information concerning share ownership by others of in the profiled company DEFT . The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to DEFT industry; (b) market opportunity; (c) DEFT business plans and strategies; (d) services that DEFT intends to offer; (e) DEFT milestone projections and targets; (f) DEFT expectations regarding receipt of approval for regulatory applications; (g) DEFT intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) DEFT expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute DEFT business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) DEFT ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) DEFT ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) DEFT ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of DEFT to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) DEFT operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact DEFT business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing DEFT business operations (e) DEFT may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
- The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Defence Therapeutics
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled Defence Therapeutics and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Defence Therapeutics or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Defence Therapeutics Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Defence Therapeutics’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Defence Therapeutics future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Defence Therapeutics industry; (b) market opportunity; (c) Defence Therapeutics business plans and strategies; (d) services that Defence Therapeutics intends to offer; (e) Defence Therapeutics milestone projections and targets; (f) Defence Therapeutics expectations regarding receipt of approval for regulatory applications; (g) Defence Therapeutics intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Defence Therapeutics expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Defence Therapeutics business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Defence Therapeutics ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Defence Therapeutics ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Defence Therapeutics ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Defence Therapeutics to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Defence Therapeutics operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Defence Therapeutics business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Defence Therapeutics business operations (e) Defence Therapeutics may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Defence Therapeutics or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Defence Therapeutics or such entities and are not necessarily indicative of future performance of Defence Therapeutics or such entities.
